Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
PURESIS® TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): PURESIS ® TABLETS COMPOSITION: Each tablet contains 40 mg Furosemide . PHARMACOLOGICAL CLASSIFICATION: A 18.1 Diuretics PHARMACOLOGICAL ACTION: Puresis exerts its diuretic action by virtue of its saluretic properties. Experimental evidence has proved that Furosemide acts by reducing the reabsorption of sodium and water at the levels of the proximal convoluted tubule, ascending limb of Henle's loop and the distal convoluted tubule. Puresis thus acts throughout the tubule, and it is today believed that the action of Furosemide on the loop of Henle is the most important action on the nephron. In situations where other methods of treatment fail to induce diuresis, it is often possible with Puresis, to increase the excretion of sodium and water, even when the glomerular filtration rate is markedly impaired. Puresis lowers pathologically raised blood pressure levels, but does not affect normal values. With Puresis administration, the onset of action is rapid, usually within half-an-hour. Peak action is usually achieved after 2 hours, and the duration of action of the drug is 4 –5 hours. INDICATIONS: (a) Ascites due to cirrhosis of the liver, mechanical obstruction or cardiac failure. (b) To prevent oliguria from progressing to complete anuria. (c) Cardiac oedema. (d) Hypertension of mild to moderate degree. (e) Oedema occurring during the last three months of pregnancy – pre-eclamptic toxaemia and eclampsia. (See warnings). CONTRA-INDICATIONS: Patients who exhibit hypersensitivity to furosemide. In hepatic coma and in states of electrolyte depletion. Puresis is contra-indicated if increasing azotaemia and oliguria occur during treatment of severe progressive renal disease. Lactating women. WARNING: In pregnancy Read the complete document